This will include launching a marketing strategy and program execution
to drive product awareness and sales. GenWay Biotech will bear all
responsibility for these activities. The potential value of these
agreements is at least $15.8 million over a 5-year period.
"The US and Canada are major world markets for in vitro diagnostic
products," says Douglas MacLellan, chairman and CEO of AMDL. "We
believe that GenWay Biotech is well positioned to drive market adoption
with CLIA laboratories in these significant markets.
"This is a substantial moment in the history of AMDL's Tustin-based
operations – not only does this agreement validate DR-70 as a viable
cancer diagnostic product, it puts AMDL's diagnostic division on a
solid path to profitability," continues MacLellan